Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I first-in-human ascending single-dose study of ANF-Rho versus Neulasta and placebo in healthy volunteers
NL-OMON41975Phase 1Active, not recruiting
- Sponsor
- Prolong Pharmaceuticals
- Start
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, double-blind trial of ANF-RHO in neutropenia (3 arms), sponsored by Prolong Pharmaceuticals. Primary endpoint: Plasma pharmacokinetic profile of ANF-Rho. Started Sep 2014; status: active, not recruiting.
02
Drugs
ANF-RHO
03
Conditions
neutropenia
Beyond the preview
Go deeper on NL-OMON41975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41975.